Acute efficacy of telcagepant in migraine patients with prior use of opioids

Excellent Tolerability But Relatively Low Initial Clinical Efficacy of Telcagepant in Migraine: A Response

“…We believe that by targeting a different aspect of migraine pathophysiology, a CGRP receptor antagonist such as telcagepant has the potential to help address this large unmet medical need and provide additional treatment options for patients. Based on questionnaires about patient's historical treatment response in the phase 3 studies, we have found that the efficacy of telcagepant is not impacted by whether or not patients previously responded to triptans ≥ or <75% of time, to nonsteroidal anti‐inflammatory drugs ≥ or <75% of time, or to opioids ≥ or <75% of time 4,5 …”